First Drug to Demonstrate Efficacy in Patients With CTEPH
First drug to demonstrate efficacy in patients with CTEPH
Filed under: drug treatment news 2010
“These study results with riociguat are encouraging because it is the first drug treatment which has demonstrated in a Phase III trial such improvements in inoperable CTEPH or in difficult to treat patients with persistent or recurrent pulmonary …
Read more on Pharmacy Europe
Heroin addiction soars in Maine as treatment cuts take effect
Filed under: drug treatment news 2010
The American Society of Addiction Medicine reports that misuse of prescription drugs has dropped about 15 percent nationally since 2010, while heroin use has doubled since 2007. Publicker said he's unaware of figures that document heroin use in Maine, …
Read more on Kennebec Journal
Will County Drug Court participants get new place to call home
Filed under: drug treatment news 2010
Drug Court, presided over by Judge Carla Alessio-Policandriotes, allows substance abusers who commit non-violent offenses to enroll in programs to help them find treatment and employment by staying drug free and submitting to random tests. Graduates …
Read more on Joliet Herald News
More drug treatment news 2010 Resources
OPENING SESSION – ISMRM
MRI versus Multislice Helical CT -Clinical Efficacy in the Assessment of Peripheral Quantification of Regional Human Leg Muscle Perfusion Using First-pass Magnetic Ability of MR Cholangiography to Demonstrate Stent Position and Luminal Diameter in Patients with Biliary Endoprostheses: In Vitro … Document Viewer
Update On Therapies For Pulmonary Hypertension
Able and is still considered the first-line therapy for NYHA class IV patients [25]. More recently, the efficacy of continuous Drug ther-apy in CTEPH is now being studied on the basis efficacy of bosentan in patients with inoperable CTEPH. … Retrieve Here
… View Document
Non-blinded evaluation of 40 patients with IPAH was terminated prematurely due to predicted failure to demonstrate a included 33% of iloprost-treated patients with CTEPH.34 Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients … Retrieve Content
Current And Future Therapies For Pulmonary Hypertension
Could demonstrate a survival benefit in patients with PAH who decreased their first-line prostanoid by several experts for moderately to severe ill patients with PAH and CTEPH. and efficacy of bosentan in patients with inop-erable CTEPH. … Visit Document
Catheterization.However,even patients who demonstrate seen in CTEPH patients. There was no significant efficacy of the drug as first line monotherapy in patients … Fetch Document
PAH: The Shortcomings Of The CurrentGuidelines
Excessive sample sizes to demonstrate differences among activetreatments IIa.. weight of evidence/opinion is an favour usefulness/efficacy 15.Galié, Bosentanin Patients With Eisenmenger S, Circulation 2006 … Access Full Source
From Drug Discovery To Therapeutic Franchises
First submission First approval PMS Launch key markets Objective • The primary objective of the study was to demonstrate that bosentan Exploratory Study in IPF • Evaluating the safety and efficacy of macitentan in patients suffering from IPF … View Full Source
Riociguat For Pulmonary Arterial Hypertension December 2010
• Calcium channel blockers nifedipine and diltiazem, indicated for patients who – demonstrate Efficacy and safety . Trial NCT00454558; mono- or add-on therapy; CTEPH or PAH; phase II and phase II AEs experienced in 65/75 (87%), 42 (56%) were drug-related; i … Get Document
PAH – CVC | Cardiovascular Consultants, Ltd
Only 40-50% of CTEPH patients have a history of previous episodes of acute PE. in which the two drugs were used is opposite than what usually occurs (oral drug first and of those patients appropriately treated with CCB is nearly normal, compared with patients who do not demonstrate … Access Doc
Advances In Pharmacotherapy Of PAH
• 62.5 mg bid for first 4 weeks • Up-titration to a maintenance dose of 125 mg • OBJECTIVE: To demonstrate the efficacy of bosentan in patients with inoperable CTEPH or persistent/recurrent • Potential Risks: Drug–drug interactions due to CYP- … View This Document